Detection of circulating tumor in lymphoma patients using dPCR-based liquid biopsy in clinical routine, an observational study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034686

Enrollment

400

Registered

2024-08-06

Start date

2024-04-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71.9

Interventions

Group 1: In the present project and within an observational study, the data collected during routine testing of lymphoma-specific mutations with ddPCR assays in body fluids of patients with B-cell lym

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Suspected CNS-lymphoma, suspected lymphoma progression or MRD monitoring lymphoma

Exclusion criteria

Exclusion criteria: < 18 years

Design outcomes

Primary

Measure	Time frame
Reason for and implications of ctDNA analyses from lymphoma patients: Systematic evaluation of clinical data assessing the reasons for ctDNA analyses from CSF, blood plasma and vitreous fuid and their implications on patient management.	—

Secondary

Measure	Time frame
Systematic evaluation of the molecular results: ctDNA detection rates, ctDNA concentrations, turnover time, and other molecular specifics related to the dPCR analyses will be evaluated.	—

Countries

Austria, Germany

Contacts

Public ContactFlorian Scherer

Universitätsklinikum Freiburg Medizinische Klinik I

florian.scherer@uniklinik-freiburg.de79106

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026